Pfizer Inc. / Biocon Limited (biosimilar insulin license)

Diabetes Mellitus (Insulin-requiring)

$15.0B Global insulin market estimated ~$15B at deal time (Biocon chair Kiran Mazumdar-Shaw)

Disease Overview

Diabetes mellitus is a chronic metabolic disease in which insulin is absent (Type 1) or insufficiently effective (Type 2). Insulin therapy — recombinant human insulin and analogs (glargine, aspart, lispro, detemir) — is mandatory for Type 1 and used in advanced Type 2. Insulin is biologically complex enough that biosimilar copies require dedicated clinical and analytical packages.

Competitive Landscape

In 2010 the global insulin market was a tightly held oligopoly: Sanofi (Lantus/glargine), Novo Nordisk (NovoLog/aspart, Levemir/detemir), and Eli Lilly (Humalog/lispro, Humulin) controlled the vast majority of revenue, with Sanofi's Lantus alone exceeding $5B in annual sales. Biocon, India's largest biotech, had developed biosimilar versions of recombinant human insulin, glargine, aspart, and lispro and was already commercializing them in India and emerging markets under Insugen and Basalog brands. Pfizer paid $200M upfront plus up to $150M in milestones for global commercialization rights (excluding Germany, India, Malaysia, where rights were co-exclusive). The deal was strategically aimed at the patent-cliff opportunity on Lantus and Humalog and at filling the hole left by Pfizer's failed Exubera inhaled insulin. Within 17 months the partnership collapsed (March 2012) — Biocon kept the $200M upfront plus most of $100M escrow, and rights reverted [https://www.gabionline.net/biosimilars/news/Pfizer-and-Biocon-s-biosimilar-insulin-deal-is-off]. The termination signaled to the industry that biosimilar insulins were harder and less lucrative than expected, particularly in the US where regulatory pathway clarity took years longer (Lilly's Basaglar finally reaching market via 505(b)(2) in 2016).